TABLE 3.
Clinical factors associated with persistent Scedosporium isolation, unadjusted, and adjusteda
| Unadjusted | Adjusteda | |||||
|---|---|---|---|---|---|---|
| Odds ratio | 95% CI | P-value | Odds ratio | 95% CI | P-value | |
| Demographics | ||||||
| Baseline age, 10 year increments | 1.15 | 1.06, 1.25 | 0.001 | 1.15 | 1.03, 1.28 | 0.01 |
| Female | 1.38 | 1.11, 1.73 | 0.01 | 1.23 | 0.98, 1.54 | 0.07 |
| White vs non-white | 1.26 | 0.76, 2.10 | 0.37 | |||
| F508del | 1.08 | 0.91, 1.28 | 0.38 | |||
| Disease characteristics | ||||||
| Pancreatic insufficiency | 1.15 | 0.81, 1.64 | 0.44 | |||
| Baseline FEV1 % predicted, 10% increments | 0.87 | 0.83, 0.90 | <0.001 | 0.96 | 0.90, 1.01 | 0.11 |
| CFRD | 1.53 | 1.19, 1.95 | 0.001 | 0.95 | 0.73, 1.23 | 0.68 |
| Treatments | ||||||
| Inhaled antibiotics | 3.09 | 2.30, 4.14 | <0.001 | 2.10 | 1.52, 2.90 | <0.001 |
| Macrolide | 1.94 | 1.52, 2.47 | <0.001 | 1.20 | 0.92, 1.56 | 0.18 |
| IV antibiotic courses, number in baseline year | 1.27 | 1.21, 1.34 | <0.001 | 1.13 | 1.06, 1.21 | <0.001 |
| Inhaled corticosteroid | 1.30 | 1.03, 1.63 | 0.03 | 0.88 | 0.70, 1.12 | 0.31 |
| Infections | ||||||
| Pseudomonas aeruginosa | 1.73 | 1.36, 2.21 | <0.001 | 1.01 | 0.77, 1.32 | 0.95 |
| MRSA | 1.04 | 0.82, 1.33 | 0.75 | |||
| Burkholderia cepacia | 1.22 | 0.68, 2.19 | 0.50 | |||
FEV1, Forced expiratory volume in 1 second; CFRD, Cystic fibrosis related diabetes; IV, intravenous; MRSA, methicillin resistant Staphylococcus aureus. Bold effect estimates are the ones that are statistically significant.
a
Adjusted model includes baseline age, female, FEV1 percent predicted, CFRD, inhaled antibiotics, macrolide, IV antibiotic courses per year, inhaled corticosteroids, Pseudomonas aeruginosa co-infection, and total number of encounters during study period.